HLB Co., Ltd. (KOSDAQ:028300)
52,400
+300 (0.58%)
At close: Feb 11, 2026
HLB Co., Ltd. Revenue
HLB Co., Ltd. had revenue of 22.11B KRW in the quarter ending September 30, 2025, with 30.43% growth. This brings the company's revenue in the last twelve months to 80.73B, up 55.49% year-over-year. In the year 2024, HLB Co., Ltd. had annual revenue of 68.13B with 58.80% growth.
Revenue (ttm)
80.73B
Revenue Growth
+55.49%
P/S Ratio
86.23
Revenue / Employee
527.66M
Employees
153
Market Cap
6.96T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | 56.18B | 17.76B | 46.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SK Biopharmaceuticals | 675.41B |
| SK bioscience | 624.03B |
| PharmaResearch | 496.03B |
| Hugel | 404.19B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
| OliX Pharmaceuticals | 10.18B |
| D&D Pharmatech | 8.36B |